US2012190688A1PendingUtilityA1

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

62
Assignee: BRUNCKO MILANPriority: May 26, 2009Filed: Mar 26, 2012Published: Jul 26, 2012
Est. expiryMay 26, 2029(~2.9 yrs left)· nominal 20-yr term from priority
A61P 37/00A61P 43/00A61P 37/06A61P 35/00A61P 35/02A61P 35/04C07D 471/04C07D 209/82C07D 519/00C07D 401/14A61K 31/496A61K 31/437C07D 403/12C07D 401/12Y02A50/30
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Claims

exact text as granted — not AI-modified
1 .- 8 . (canceled) 
     
     
         9 . The compound 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof. 
     
     
         10 .- 32 . (canceled) 
     
     
         33 . A pharmaceutical composition comprising an excipient and a therapeutically effective amount of 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide or a pharmaceutically acceptable salt thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.